The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

No merger talk here: Novartis just wants to be friends with Roche, chairman says

Novartis Chairman Joerg Reinhardt may be chatting with his colleagues at Roche. His company may want to work more closely with its hometown rival. But joining forces in a merger? No, thank you.

Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months

Unlike every other Big Pharma company in the world, Novartis tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure.

Novartis' pitch to join trial data sharing bandwagon gets frosty reception

Johnson & Johnson was cautiously lauded for its clinical trial data-sharing initiative, but Roche's project was pilloried. Now Novartis has joined its Swiss peer in rolling out an underwhelming transparency program.

Novartis takes the transparency 'pledge' as Big Pharma critics pounce

Now that many of the major pharma companies have promised to open up, at least somewhat, on their clinical trial data, Novartis has decided to take the pledge as well. But rather than earn plaudits from longtime critics who have castigated the industry for years of secrecy about their clinical trials, it's only likely to stir a growing backlash among commentators who view these moves as far too limited, spurred primarily by a more ambitious approach from European regulators who want to force open the floodgates.

Novartis to shutter R&D site in June as global reorganization unfolds

Once Novartis put out the word that it would start "consultations" about the future of its R&D site in Horsham, U.K., there was never much doubt that the pharma giant would go ahead and close the operation, putting the futures of some 400 staffers and 170 consultants in doubt. On Wednesday the pharma giant confirmed those expectations.

Ranbaxy scrambles to fix problems that challenge its exclusives

In an effort to get itself into a place where it can again ship from its FDA-approved plants in India, Ranbaxy Laboratories says it is taking a hard look at how it runs its API operations.

The Vasella era ends as Novartis says goodbye to his policies--or is it good riddance?

Today in Basel, Novartis shareholders ratified Joerg Reinhardt's move into the chairman's seat. That might be considered the final, official farewell in former Chairman Daniel Vasella's long goodbye. But shareholders also approved other, more nitty-gritty changes in corporate governance that explicitly undo some of Vasella's work.

Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit

Last week, we heard that Merck's consumer unit was bearing down on a sale, with a price of $10 billion-plus. Now, Reuters sources say the deal could be worth up to $12 billion, with several consumer and healthcare companies in on the hunt.

After a Phase II win, Novartis hints at an early app for its skin cancer pill

Novartis said its in-development skin cancer drug aced a Phase II study, completely eradicating the disease in some patients, and now the company plans to loop in regulators, possibly signaling an early FDA application for the treatment.

Novartis advertising probe intensifies with Tokyo office raid

Prosecutors came knocking at Novartis' Tokyo offices, stepping up their probe of the Swiss drugmaker's Diovan advertising. The Japanese authorities raided the local unit as part of an investigation into allegations that Diovan data was manipulated, and advertising for the blood pressure drug relied on that rigged data.